GlassScriptPhysician profile
Henry Tellez
NPI 1861560401
$2,938.06
in general payments reported to CMS, 2019-2025
36 companies · $1,855 in 2025
The $1,855 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $168 · 2023: $121 · 2024: $794 · 2025: $1,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $343.02 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $261.11 | 2024-2025 | Nuplazid |
| Lilly USA, LLC | $182.73 | 2024-2025 | Kisunla, Zepbound, Amyvid |
| Abbott Laboratories | $167.73 | 2022 | |
| Biogen, INC. | $161.74 | 2024-2025 | Tysabri, Leqembi, Skyclarys |
| Lundbeck LLC | $149.39 | 2024-2025 | Vyepti |
| Abbvie INC. | $142.82 | 2024-2025 | |
| Nevro Corp. | $121.06 | 2023 | Senza |
| Celgene Corporation | $107.21 | 2024-2025 | Zeposia |
| Boston Scientific Corporation | $100.32 | 2024 | Watchman Flx |
| Ucb, INC. | $97.70 | 2024-2025 | Nayzilam, Rystiggo, Briviact |
| Neurocrine Biosciences, INC. | $86.24 | 2025 | |
| Neurelis, INC. | $85.28 | 2024-2025 | Valtoco |
| Amgen INC. | $74.51 | 2024-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $70.19 | 2024-2025 | Crexont, Ongentys |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Tellez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.